Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.63 |
| ▸ | TUBB | P07437 | 1/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.63 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7623120 | 1.00 | MAPT (0.74) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL6026757 | 0.88 | MAPT (0.69) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL6026750 | 0.88 | MAPT (0.69) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL4332218 | 0.85 | MAPT (1.00) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL4332222 | 0.85 | MAPT (1.00) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL8257172 | 0.85 | MAPT (0.74) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL7326815 | 0.83 | MAPT (0.53) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL4698346 | 0.81 | MAPT (0.60) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL4698350 | 0.81 | MAPT (0.67) | MAPTGAACYP1A2CYP3A4RAB9A | |
| SCHEMBL9668293 | 0.81 | RAB9A (0.77) | MAPTGAACYP1A2CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444706-B2 | ANTIINFLAMMATORY AGENTS; MICROBIOCIDES; ANTITUMOR AGENTS; VIRICIDES | CANCER RESEARCH VENTURES LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| US-20010023251-A1 | Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | BIOSPHINGS AG (DE) | 2001-09-20 | — | — | US | disclosed |
| US-6284798-B1 | ALKYLAMINOGUANDINES | CANCER RESEARCH VENTURES LIMITED (GB) | 2001-09-04 | — | — | US | disclosed |
| EP-0918750-A1 | NEW GUANIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | Amtmann, Eberhard (DE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997045401-A1 | NEW GUANIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023251-A1 | Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | GMPS, GANC, GUCY1A2 | MAPT 2093/4885GAA 70/4885CYP1A2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.